Axitinib

Licensed by Pfizer Catalog No.S1005 Synonyms: AG 013736

Axitinib Chemical Structure

Molecular Weight(MW): 386.47

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 120 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Representative confocal image (10 x objective) of individual spheroids fixed, sectioned, and then stained for vimentin (green) and DNA (DAPI, blue). Vimentin protein expression from sections quantitated from multiple replicate spheroid treatments with U0126 and axitinib using ImageJ software.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

    VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

  • Western blot analysis of ERK phosphorylation in HUVECs stimulated for 10 min with AGR2 coupled with or without FGF/VEGF. The concentration of AGR2 is 500 ng/ml. The concentration of VEGF is 5 ng/ml. PD173074: FGFR inhibitor; Axitinib: VEGFR inhibitor (2 nm); BEV: VEGF antibody bevacizumab (5 μg/ml). Quantification of ERK activity was performed by normalizing phosphorylated ERK to β-actin, untreated control (lane 1) was set to 1. All data represent four independent biological replicates and shown as means±s.d. Asterisks indicate significant differences (*, Pless than or equal to0.05; **, Pless than or equal to0.01).

    Oncogene, 2017. Axitinib purchased from Selleck.

    Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Axitinib purchased from Selleck.

  • Axitinib treatment blocks VEGFR2 phosphorylation.

    HUVECs were starved O/N in EBM-2 basal medium with 1% FBS and antibiotic. Cells were pre-treated with Axitinib at 0.1, 1 and 10 nM concentrations. VEGF stimulation was 50 ng/ml for 10 minutes before cells were collected and protein isolated for immunoprecipitation with VEGFR2 followed by immunoblotting with VEGFR-2 and phospho-VEGFR-2.

     

     

    Dr. Cheri Pasch of UW Madison. Axitinib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).
Targets
VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)
PDGFRβ [1]
(Porcine aorta endothelial cells)
0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM 1.6 nM
In vitro

Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NImyXWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMECwNFUyOyEQvF2= MX\TRW5ITVJ?
NCI-H1703 NH3ySGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIi0O5JKSzVyPUCuNFAxQTB{IN88US=> NU\0eoI4W0GQR1XS
KASUMI-1 Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwMEC2PFIh|ryP NGq3eFlUSU6JRWK=
CGTH-W-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTpfIlLUUN3ME2wMlAxPzJ{IN88US=> NEDXcYlUSU6JRWK=
A204 M4fobGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMEC5PVIh|ryP NEjSUINUSU6JRWK=
HOP-62 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULBOGY6UUN3ME2wMlExQDN4IN88US=> MkHaV2FPT0WU
H-EMC-SS NI\IZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmm2TWM2OD1yLkGxNFA2KM7:TR?= NWjw[ZloW0GQR1XS
KU812 M37jeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PWOGlEPTB;MD6xOlU4PyEQvF2= MnnPV2FPT0WU
EM-2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPYS|lXUUN3ME2wMlE3QDF4IN88US=> MXjTRW5ITVJ?
LAMA-84 NETLVZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInYdnBKSzVyPUCuNVc3PjVizszN MmXrV2FPT0WU
JAR NF64b3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfpfI9KSzVyPUCuNlM6QDlizszN Mmm5V2FPT0WU
G-361 MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\YNGlEPTB;MD6zNlMzPSEQvF2= NGHvNHBUSU6JRWK=
KG-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGf1NmVKSzVyPUCuN|c3PDJizszN NUHxZnNlW0GQR1XS
BV-173 MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwM{mzNkDPxE1? MkW2V2FPT0WU
K5 NX7DbFRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LUU2lEPTB;MD60NlEzPyEQvF2= NGTtOWxUSU6JRWK=
MEG-01 NGntRmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3njUmlEPTB;MD60NlM3OSEQvF2= MlzwV2FPT0WU
MFM-223 NWHCWHNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;aTWM2OD1yLkS0O|c3KM7:TR?= M2PCeXNCVkeHUh?=
BE-13 M4TFR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwNUGwNFgh|ryP MmjiV2FPT0WU
NEC8 NH7pcIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\CUmlEPTB;MD63NlEyOyEQvF2= Ml:2V2FPT0WU
SW756 M{jqS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn2yTWM2OD1yLkm5PFQ3KM7:TR?= MWTTRW5ITVJ?
A2780 NV3ae4J3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmCzTWM2OD1zLkCxNVQ3KM7:TR?= MkXYV2FPT0WU
NB14 NUHKUJJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTFwMEG4NFEh|ryP MVHTRW5ITVJ?
H4 NHf2SJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHmNYVzUUN3ME2xMlA3PDJ{IN88US=> M4TOXnNCVkeHUh?=
SK-OV-3 M1rxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPTPJVUUUN3ME2xMlA3PjN|IN88US=> NInxRYtUSU6JRWK=
AN3-CA MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXITWM2OD1zLkC4N|g6KM7:TR?= Ml:yV2FPT0WU
A427 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHkTWM2OD1zLkGwN|gyKM7:TR?= NVHOSIhYW0GQR1XS
ES7 NXiyXJF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTFwMUGzN|Qh|ryP MkfLV2FPT0WU
AGS M2XsVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3PPYJjUUN3ME2xMlEyOzl3IN88US=> MYXTRW5ITVJ?
G-402 NI[3U2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfKSVJKSzVyPUGuNVQ3QTRizszN NWftRYJpW0GQR1XS
ES5 NE\xdZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nuUWlEPTB;MT6xO|I1QCEQvF2= M1LrSXNCVkeHUh?=
DEL MkfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP0TWM2OD1zLkK1OFU4KM7:TR?= NUD1fWJHW0GQR1XS
NB10 NXjLfGtDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXv2dI9KUUN3ME2xMlMzPTV5IN88US=> NG\5coFUSU6JRWK=
NCI-H1581 M4TkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfETWM2OD1zLkO5NFQzKM7:TR?= Mmm1V2FPT0WU
D-566MG NXXrZldOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\IdJhKSzVyPUGuOFA3QDNizszN M3nEeHNCVkeHUh?=
LXF-289 NWrIelRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTFwNEO5PVYh|ryP NWHOR2V5W0GQR1XS
BT-549 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DsfGlEPTB;MT61OlkxQSEQvF2= NGDVVHlUSU6JRWK=
NKM-1 NWnje21nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;vTnFKSzVyPUGuOlA2PTZizszN NGD6OXJUSU6JRWK=
SW780 NXfncFBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTTXmNKSzVyPUGuOlUyPThizszN NI\IRVVUSU6JRWK=
NCI-H292 NV;uRpd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTFwNk[zPFMh|ryP MYrTRW5ITVJ?
HMV-II NHuzXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2mzbmlEPTB;MT63NFQ5QCEQvF2= MkfYV2FPT0WU
ALL-PO NGntPVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[zTWM2OD1zLkiwNFE2KM7:TR?= M3HGW3NCVkeHUh?=
UACC-257 MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDPc2hKSzVyPUGuPFIyPjNizszN NVf1SId5W0GQR1XS
PA-1 M4rsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fwZmlEPTB;MT64NlczPSEQvF2= MoPDV2FPT0WU
HD-MY-Z MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDsW3NKSzVyPUGuPFYzQDFizszN MYHTRW5ITVJ?
HSC-4 NFvPT|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF64TmRKSzVyPUGuPVM5OzlizszN NVTmc2pKW0GQR1XS
GCT NWfhUGRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTJwMEC5NVYh|ryP Mk\1V2FPT0WU
RT-112 NXnjUFRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLyZ5FKUUN3ME2yMlE{PDJ2IN88US=> MUfTRW5ITVJ?
A172 NHuzcGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL6TWM2OD1{LkGzOlA3KM7:TR?= Ml\IV2FPT0WU
HCE-T MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXz1NFdiUUN3ME2yMlIxPTl6IN88US=> MXPTRW5ITVJ?
YH-13 M3XCc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXiR29KSzVyPUKuNlE3PzFizszN MmXiV2FPT0WU
DK-MG NGHNR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHT0SnFKSzVyPUKuNlM5OzRizszN MoTqV2FPT0WU
ACN MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTvbFlKSzVyPUKuNlM5PzVizszN MXfTRW5ITVJ?
VA-ES-BJ NHzkWHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTJwMkS5OVch|ryP NY\4ZWVqW0GQR1XS
L-363 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJwMkiwOlEh|ryP NXm5SI4{W0GQR1XS
HuH-7 NVz2dm1ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJwNEKxOlUh|ryP MYfTRW5ITVJ?
A4-Fuk MoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXRXGxlUUN3ME2yMlQ4OTZ6IN88US=> NG\sZ4dUSU6JRWK=
T-24 NULXTGhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HqXGlEPTB;Mj60PFA{PyEQvF2= Ml;RV2FPT0WU
GOTO MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHIVIFXUUN3ME2yMlU{ODF|IN88US=> MmD6V2FPT0WU
MV-4-11 NXviOI1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v0[mlEPTB;Mj61PVE3QSEQvF2= MlXmV2FPT0WU
DMS-114 NUHPdXlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\Y[Jh4UUN3ME2yMlY3OzR3IN88US=> NEX5S2JUSU6JRWK=
MHH-NB-11 NU\uNo5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnMNpZzUUN3ME2yMlcxOjl7IN88US=> MYrTRW5ITVJ?
CHP-212 M{S3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHEd|BKSzVyPUKuPFIxQTFizszN MUjTRW5ITVJ?
DMS-273 NYi3VHd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJwOUCyNFch|ryP MWnTRW5ITVJ?
SF295 NXjrdW12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkf1TWM2OD1|LkCyOVk4KM7:TR?= M3G3dHNCVkeHUh?=
NCI-H1563 M{joT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLnTWM2OD1|LkG1NFA2KM7:TR?= NGq4WHpUSU6JRWK=
NCI-H446 NVjP[HZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlr6TWM2OD1|LkKyPFA2KM7:TR?= MoDqV2FPT0WU
HCC1806 NGjj[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXP1OXdmUUN3ME2zMlI4PjV5IN88US=> MorWV2FPT0WU
SF126 M2\KeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3oOYtKSzVyPUOuN|AxOTdizszN MoTZV2FPT0WU
SW982 NYfLZXpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DXV2lEPTB;Mz6zN|g4PSEQvF2= NYP1d29pW0GQR1XS
ES8 NWX0T|BpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHWe5hKSzVyPUOuN|Q6QTlizszN Mn\XV2FPT0WU
SCC-4 Mn7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHYcXRmUUN3ME2zMlUxOzl4IN88US=> M{XEXXNCVkeHUh?=
RPMI-8226 NFzmeFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37vR2lEPTB;Mz62NlYyPiEQvF2= Ml;wV2FPT0WU
EW-11 NFziPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4D2NGlEPTB;Mz62N|AzOiEQvF2= MUTTRW5ITVJ?
COR-L105 NFi2e3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoKxTWM2OD1|Lk[zN|M1KM7:TR?= NIPJ[GpUSU6JRWK=
ES1 NGfZV5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTNwOEOwPVQh|ryP NFrJeGdUSU6JRWK=
KMOE-2 NG[0[XdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWG1PFFZUUN3ME2zMlkyQDB6IN88US=> Mn\JV2FPT0WU
ABC-1 Mn;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXOU5lbUUN3ME2zMlk{QTFzIN88US=> M{XGVXNCVkeHUh?=
NCI-H526 NFjlZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTNwOUmxNlYh|ryP MofuV2FPT0WU
HCC1395 MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LjPGlEPTB;Mz65PVQ5PCEQvF2= MVPTRW5ITVJ?
DU-145 M2raVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7F[4RRUUN3ME20MlEzQDJ3IN88US=> MXHTRW5ITVJ?
JEG-3 NXfnO3NYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LzdGlEPTB;ND6xOVkyPiEQvF2= M{Kz[HNCVkeHUh?=
HCC1187 NGG5fppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYSzWJBkUUN3ME20MlIyPTl5IN88US=> M{nyc3NCVkeHUh?=
LC-2-ad M1i2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTRwMkKxO|ch|ryP MXvTRW5ITVJ?
ONS-76 MnXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\mTWM2OD12LkK0NVkzKM7:TR?= M{XJd3NCVkeHUh?=
CAL-27 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTRwMkSzOFQh|ryP M1vTVHNCVkeHUh?=
8-MG-BA NFPVPXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\KdGJKSzVyPUSuNlY3PThizszN MX\TRW5ITVJ?
HGC-27 M2joWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;KfWZJUUN3ME20MlI6PjZizszN NVG2cFVWW0GQR1XS
Hs-578-T NESxZY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfhcGd7UUN3ME20MlMyPDZ6IN88US=> NIfQfGpUSU6JRWK=
EW-1 NIPLSlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3KSIc3UUN3ME20MlU{ODF2IN88US=> NWrGfHNsW0GQR1XS
SW1573 M4HIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTRwNUWxOlMh|ryP MWfTRW5ITVJ?
SNU-423 MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEH1U4tKSzVyPUSuOlA4QSEQvF2= MkHOV2FPT0WU
HOS NIjpXWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2G0fGlEPTB;ND62PVc4KM7:TR?= MXjTRW5ITVJ?
LB1047-RCC NFjsXJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fvXGlEPTB;ND64NVQyQCEQvF2= MW\TRW5ITVJ?
ChaGo-K-1 NXLkVJp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUOzdXhOUUN3ME20Mlg6ODR6IN88US=> M1;YZXNCVkeHUh?=
A3-KAW M1rSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDOTWM2OD12Lkm3N|UzKM7:TR?= NHns[ZlUSU6JRWK=
CAS-1 NIrzeJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7iZ4pKSzVyPUSuPVk6ODhizszN M4PaNnNCVkeHUh?=
NBsusSR M3;kb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkW5TWM2OD13LkCzOVE1KM7:TR?= M{j6NXNCVkeHUh?=
KM12 NUXx[4t[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Oy[mlEPTB;NT6yPVgzPyEQvF2= NIO0eHdUSU6JRWK=
NCI-H1155 NGjJXlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2j2N2lEPTB;NT6zPFE5PSEQvF2= MnzHV2FPT0WU
EFM-19 NYXKWWZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;wTWM2OD13LkSxO|M4KM7:TR?= NUDVOYxOW0GQR1XS
D-392MG NEDaZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTVwNUe4OFkh|ryP M17jV3NCVkeHUh?=
JVM-3 NEXJToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrZU45KSzVyPUWuO|I{OjVizszN MYLTRW5ITVJ?
EW-16 M3LGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlz4TWM2OD13Lke1OVg{KM7:TR?= NUfQNpp[W0GQR1XS
KARPAS-45 M1PXW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILSdlFKSzVyPUWuPFQ{OjVizszN MVfTRW5ITVJ?
NCI-H28 NI\jZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXJTWM2OD13Lki3PVE5KM7:TR?= M4\o[3NCVkeHUh?=
COLO-829 NGHzfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTVwOUG1NFQh|ryP MlnIV2FPT0WU
KM-H2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrpRmNKSzVyPUWuPVI{QTVizszN NIG5N2JUSU6JRWK=
NCI-H82 M2fvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jxOGlEPTB;NT65Nlc4OSEQvF2= NF71d5lUSU6JRWK=
OAW-42 NYezUo9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTVwOUi4NlEh|ryP M3TpeHNCVkeHUh?=
A704 NITQe2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXjSFJKSzVyPU[uNVA2PzRizszN M1PuZXNCVkeHUh?=
NCI-H1048 Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrHUFFvUUN3ME22MlExPTl7IN88US=> MY\TRW5ITVJ?
LOXIMVI MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\OUodIUUN3ME22MlEyOjR6IN88US=> NX2ycFFpW0GQR1XS
MKN45 NVHZXFJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTZwMk[wNVYh|ryP Mlm2V2FPT0WU
D-502MG MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTD[FJKSzVyPU[uNlg5PTdizszN M{XTVnNCVkeHUh?=
HUTU-80 M{DaZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELkdI5KSzVyPU[uOFE3QDhizszN MmHJV2FPT0WU
S-117 NVyzOpk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGG3Z3ZKSzVyPU[uOVAzPjdizszN M1XpSHNCVkeHUh?=
HCC1569 NYfoVm1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIS3UndKSzVyPU[uOVM4OzdizszN MUHTRW5ITVJ?
J-RT3-T3-5 Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4P1WmlEPTB;Nj61OFU4OiEQvF2= NHXtSItUSU6JRWK=
OC-314 M3vnTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlraTWM2OD14LkmxNVU6KM7:TR?= NVjHc4llW0GQR1XS
SNU-449 Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfLTWM2OD15LkCxNFczKM7:TR?= MlziV2FPT0WU
NCI-H720 M{DheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4CydWlEPTB;Nz6xPVM1PSEQvF2= Mlz2V2FPT0WU
KP-N-YS MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTURXpkUUN3ME23MlIxPzJizszN NV3uSZNFW0GQR1XS
IGROV-1 NUmzdYNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPUTWM2OD15LkOyN|g3KM7:TR?= MojQV2FPT0WU
SK-PN-DW MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XmdmlEPTB;Nz60PFE2KM7:TR?= MonKV2FPT0WU
HCC1419 NXTXeI5GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHWTWM2OD15LkWzJO69VQ>? NIjnWXBUSU6JRWK=
HAL-01 NWjLZo1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrNTWM2OD15Lk[wOlQ1KM7:TR?= MUfTRW5ITVJ?
HCC2998 M{LUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYS2Z2lXUUN3ME23MlYxPzR|IN88US=> NF3FOlBUSU6JRWK=
SK-N-FI MmW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTdwNkOwN|Mh|ryP M{TFVHNCVkeHUh?=
GI-ME-N MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTdwNkS5N|Qh|ryP MWjTRW5ITVJ?
SW1088 NHrjUnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TYZ2lEPTB;Nz62OVgzPiEQvF2= Mn;hV2FPT0WU
IA-LM M4Da[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXHTWM2OD15Lk[4OlE{KM7:TR?= M3\ScHNCVkeHUh?=
SK-NEP-1 NVnrNYVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HEVmlEPTB;Nz62PVYyKM7:TR?= MorMV2FPT0WU
MDA-MB-415 Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfFWZNKSzVyPUeuPFkyQDZizszN MojEV2FPT0WU
COLO-800 NVf6cmlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTdwOUS0PVIh|ryP MXHTRW5ITVJ?
NCI-H2228 NIf1XZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXIVmR{UUN3ME24MlE2Pzh|IN88US=> M{fPN3NCVkeHUh?=
D-423MG MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDqN45MUUN3ME24MlIyPzJizszN NF[yb|FUSU6JRWK=
TE-1 M3O5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFywTodKSzVyPUiuOFQ{OTZizszN M1fmR3NCVkeHUh?=
NOS-1 NGezTHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jR[GlEPTB;OD61NVU{PCEQvF2= MmO3V2FPT0WU
8505C MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzsUIRKSzVyPUiuOlQ5OjRizszN NFXY[YVUSU6JRWK=
HEC-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH5bm5sUUN3ME24Mlc5PDN7IN88US=> MoTpV2FPT0WU
TE-11 NF;KXZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3nTWM2OD16Lkm5OVUyKM7:TR?= MnfxV2FPT0WU
CTB-1 MoS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUm3TlJ3UUN3ME25MlAyPDN|IN88US=> MYjTRW5ITVJ?
TGBC11TKB MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvTc|lKSzVyPUmuNFIzPDFizszN M1rBd3NCVkeHUh?=
NB17 NYiyNXJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVG2VmVUUUN3ME25MlE5QDdizszN MoDnV2FPT0WU
Becker MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnZTWM2OD17LkSxPVQ1KM7:TR?= NGHBVotUSU6JRWK=
SN12C MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHDTWM2OD17LkS1NlM1KM7:TR?= MX3TRW5ITVJ?
COLO-320-HSR M3[wNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnkTWM2OD17Lk[wNlM4KM7:TR?= NUG2T4RCW0GQR1XS
D-283MED NEHFNmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q2bGlEPTB;OT62N|A4OiEQvF2= NIXGVIVUSU6JRWK=
D-263MG M1Xaemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWj4b|BXUUN3ME25Mlg{Ozh2IN88US=> M1[3eHNCVkeHUh?=
MEL-JUSO MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPLN41KSzVyPUmuPVAyOjdizszN NX7wflhIW0GQR1XS
T98G NGKydoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVX6cJl5UUN3ME25MlkxOjB|IN88US=> MX3TRW5ITVJ?
HLE NUKw[5VQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\Fd5lKSzVyPUmuPVA6ODlizszN MU\TRW5ITVJ?
Ca9-22 NGq0XXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTrTWM2OD1zMD6wOlY2KM7:TR?= NIPCOYJUSU6JRWK=
OS-RC-2 MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrDbXVKSzVyPUGwMlExPDVizszN M2DSdXNCVkeHUh?=
T47D MlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTFyLkG1OUDPxE1? NEDRO4NUSU6JRWK=
GI-1 NXLJWpZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTFyLkO1N|Mh|ryP Ml[4V2FPT0WU
NUGC-3 NEfMXnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r5V2lEPTB;MUCuOFQxOiEQvF2= MYXTRW5ITVJ?
MDA-MB-361 NXTIRXFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTFyLkS0N|Ih|ryP NU\2NIlbW0GQR1XS
SCC-15 NISyNG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLLfZdyUUN3ME2xNE41PzF6IN88US=> NHvEcHlUSU6JRWK=
KS-1 MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M322eWlEPTB;MUCuOlMxOSEQvF2= M2LLfXNCVkeHUh?=
CAL-12T MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDmTWM2OD1zMD62N|YyKM7:TR?= Ml;pV2FPT0WU
OVCAR-4 NIPOS|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MontTWM2OD1zMD63NFY5KM7:TR?= MnrPV2FPT0WU
HuP-T4 M3jjfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTFzLkCzNlgh|ryP Mk[3V2FPT0WU
NCI-H358 NF3LVm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDOOocyUUN3ME2xNU4zPjV5IN88US=> M3fOWnNCVkeHUh?=
HO-1-N-1 Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3xc4tvUUN3ME2xNU4{Ozl6IN88US=> NYrhbnRQW0GQR1XS
NH-12 MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIr6NZRKSzVyPUGxMlU{PzhizszN MkXxV2FPT0WU
MOLT-4 MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjFWGNKSzVyPUGxMlU6QDVizszN MVPTRW5ITVJ?
K-562 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjEOZBCUUN3ME2xNU44OjR6IN88US=> NXvXRmFlW0GQR1XS
ES6 NH\tc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\LdYdKSzVyPUGxMlg2QDFizszN NX64dIVKW0GQR1XS
RO82-W-1 NHXNRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFzLkmwOlQh|ryP NHXmUphUSU6JRWK=
Ramos-2G6-4C10 NWrrSINCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPXTWM2OD1zMT65N|Ih|ryP NY\hdY14W0GQR1XS
23132-87 Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLZSVM4UUN3ME2xNk4xQDJzIN88US=> Mly0V2FPT0WU
A549 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF{LkOyPFUh|ryP NFnpfWpUSU6JRWK=
NCI-H23 NILBUVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTF{LkWwNlYh|ryP M3S3OnNCVkeHUh?=
H9 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\RfHJKSzVyPUGyMlU2PzdizszN MVfTRW5ITVJ?
LB771-HNC MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF{Lke2OUDPxE1? MmrrV2FPT0WU
QIMR-WIL M1jMNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnxN3J1UUN3ME2xNk45OjV6IN88US=> MX;TRW5ITVJ?
HSC-3 NFSxeWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TjUGlEPTB;MUKuPVI4PiEQvF2= MoHyV2FPT0WU
PFSK-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH1TWM2OD1zMj65OVA4KM7:TR?= MVnTRW5ITVJ?
ETK-1 NWnofm1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzVOWFEUUN3ME2xN{4xPzd7IN88US=> M3HrdnNCVkeHUh?=
SW1710 NHnKS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\BbGVKSzVyPUGzMlM3PDFizszN NX;XcINrW0GQR1XS
COLO-684 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXwWmdVUUN3ME2xN{41PTRzIN88US=> NW\zXIxsW0GQR1XS
RPMI-7951 NYXqW4pjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHLd45TUUN3ME2xN{42OTN4IN88US=> M3nlVHNCVkeHUh?=
A101D NF3ieJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXoeJNmUUN3ME2xN{42OzR7IN88US=> NGTBb4lUSU6JRWK=
KE-37 NHrE[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\BTWM2OD1zMz61PFg4KM7:TR?= NFPXUlNUSU6JRWK=
SiHa MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T3[GlEPTB;MUOuPFM1PiEQvF2= NIHpeplUSU6JRWK=
NCI-H226 MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Xpb2lEPTB;MUOuPFgxQCEQvF2= NFTjNVBUSU6JRWK=
DB MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTF|Lkm5Nlgh|ryP M{PVRXNCVkeHUh?=
HT-1197 NEfRWY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF2LkC4NFkh|ryP M3vZcnNCVkeHUh?=
SBC-5 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vMWGlEPTB;MUSuNVM3OiEQvF2= MYfTRW5ITVJ?
VMRC-RCZ MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[xTWM2OD1zND61O|c1KM7:TR?= MV3TRW5ITVJ?
697 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4m5VWlEPTB;MUSuOlI4KM7:TR?= NXTFRXFJW0GQR1XS
OMC-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF2Lke4PFgh|ryP M{\oSXNCVkeHUh?=
SKG-IIIa NGC0UnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHuw[GNKSzVyPUG0MlgxODFizszN NHnNV49USU6JRWK=
DOK MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HOUGlEPTB;MUSuPVk{OyEQvF2= MmnFV2FPT0WU
NCI-H2029 MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTF3LkO2NFIh|ryP NI\p[Y1USU6JRWK=
NCI-H2009 NFTIdWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\6TWM2OD1zNT61NFk2KM7:TR?= M3HSXnNCVkeHUh?=
LK-2 Ml3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\iRlM3UUN3ME2xOU43PDR7IN88US=> MULTRW5ITVJ?
NCI-H661 M4\tb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nkNWlEPTB;MUWuPVA4PSEQvF2= NWDnXnNGW0GQR1XS
GT3TKB NGLX[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTF4LkC2O|Yh|ryP M2rVd3NCVkeHUh?=
GP5d NEDrVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nQ[2lEPTB;MU[uN|QzKM7:TR?= M1\Od3NCVkeHUh?=
SK-MEL-2 MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTF4LkS0PFUh|ryP NU\scnVsW0GQR1XS
SK-UT-1 MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7qTWM2OD1zNj61OlUh|ryP NE\RNXRUSU6JRWK=
NB7 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7iTWM2OD1zNj62PVcyKM7:TR?= M3vV[HNCVkeHUh?=
NCI-H460 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF20SVFKSzVyPUG2Mlc{OjZizszN NGnUSYhUSU6JRWK=
8305C NW\rNnVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXHV|BnUUN3ME2xOk44QDd5IN88US=> MXrTRW5ITVJ?
CaR-1 NIizO3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTF4LkixNVEh|ryP NUTncmlyW0GQR1XS
D-247MG NH3EfZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTF4Lki2NlUh|ryP MlrKV2FPT0WU
LoVo NETuXWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTF4Lkm0PFgh|ryP M1zQU3NCVkeHUh?=
NCI-H2405 NXnaNpdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXlOoJKSzVyPUG3MlE6ODhizszN NUPiWGJ5W0GQR1XS
AU565 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XjbWlEPTB;MUeuNlI2KM7:TR?= MkjSV2FPT0WU
OCI-AML2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEiye4tKSzVyPUG3MlU{OTdizszN NEGzR5lUSU6JRWK=
22RV1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF5LkW4PFQh|ryP MmPnV2FPT0WU
HT-144 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XVSGlEPTB;MUeuOlU6QCEQvF2= MV;TRW5ITVJ?
HuO9 MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlS5TWM2OD1zNz63NFMyKM7:TR?= M4THSHNCVkeHUh?=
Daoy MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvtNotPUUN3ME2xO{44OTh2IN88US=> MoPIV2FPT0WU
SJRH30 Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Dv[mlEPTB;MUeuPFQ5QSEQvF2= NYfPNoRSW0GQR1XS
CHL-1 MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PlSWlEPTB;MUeuPVI1QSEQvF2= NUK2[XlpW0GQR1XS
J82 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{m3TGlEPTB;MUeuPVY{PSEQvF2= NXO5NVFwW0GQR1XS
COR-L23 MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X4TGlEPTB;MUiuNFAyOSEQvF2= MUDTRW5ITVJ?
SNU-C2B NYjaSXZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVSwSZk4UUN3ME2xPE4zOjd4IN88US=> M3LuV3NCVkeHUh?=
NCI-H1770 NWXsW|F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFKwc3hKSzVyPUG4MlQ3OTVizszN M{THSXNCVkeHUh?=
MHH-PREB-1 M13nSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPF[m5PUUN3ME2xPE42Pjl5IN88US=> MkHnV2FPT0WU
ES3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1q2RmlEPTB;MUiuOVg5OyEQvF2= MmfTV2FPT0WU
MDA-MB-231 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF6Lk[1NFIh|ryP NVviPHVpW0GQR1XS
MN-60 M1vhbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljhTWM2OD1zOT6wOVkzKM7:TR?= NFz0TWFUSU6JRWK=
EPLC-272H NYXwXGpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXrcHpMUUN3ME2xPU4{PzB6IN88US=> NGTZTpVUSU6JRWK=
SW948 MlPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUn0Xng4UUN3ME2xPU4{QTN2IN88US=> M3r6eHNCVkeHUh?=
MOLT-13 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\lZWlEPTB;MUmuOFU1PiEQvF2= MV\TRW5ITVJ?
HL-60 NXLyfZR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrFbox7UUN3ME2yNE4zOTRzIN88US=> MV;TRW5ITVJ?
CP50-MEL-B MljPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXlRWxKSzVyPUKwMlQ4PDhizszN NIjnWWZUSU6JRWK=
NTERA-S-cl-D1 M1zsOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLwTWM2OD1{MD60PVc5KM7:TR?= NWj6fm93W0GQR1XS
KINGS-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\DfmlEPTB;MkCuO|k3PyEQvF2= NVi2NGRIW0GQR1XS
DOHH-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPXbI5KSzVyPUKwMlkxPiEQvF2= NVnwdotbW0GQR1XS
BB65-RCC NVO5RWs5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fhV2lEPTB;MkCuPVI5PSEQvF2= M3vrPXNCVkeHUh?=
NB12 M3u0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2H0ZmlEPTB;MkGuNFM6PCEQvF2= NV;4ToY4W0GQR1XS
KY821 NWnMfXJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJzLkW4NkDPxE1? NUHwSFY1W0GQR1XS
PSN1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi2fnJKSzVyPUKxMlY1PTNizszN MU\TRW5ITVJ?
EGI-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHzTWM2OD1{MT63OFU1KM7:TR?= MWTTRW5ITVJ?
CTV-1 NVrBdW1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHnSlZiUUN3ME2yNk4{ODNzIN88US=> MXLTRW5ITVJ?
TI-73 NGXpboNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Tsd2lEPTB;MkKuN|Q6QCEQvF2= MVXTRW5ITVJ?
LCLC-103H MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJ{LkS3OVIh|ryP M2GwNHNCVkeHUh?=
D-542MG MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPmTWM2OD1{Mj61OVU5KM7:TR?= MlzJV2FPT0WU
ATN-1 M2LXW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjiXJpzUUN3ME2yNk43PDN7IN88US=> NFzKPZpUSU6JRWK=
SK-MEL-1 MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPKTWM2OD1{Mj64N|Y5KM7:TR?= NHnibnJUSU6JRWK=
HDLM-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV20XmxIUUN3ME2yN{4yPDd6IN88US=> M{XFdnNCVkeHUh?=
UM-UC-3 NEnxfplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\5TWM2OD1{Mz6xPVQ1KM7:TR?= MVLTRW5ITVJ?
NCI-H1573 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTJ|LkS2PFEh|ryP M4XweHNCVkeHUh?=
NCI-H520 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3nemNKSzVyPUKzMlQ6PDhizszN MlHPV2FPT0WU
ESS-1 M3zmXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkSwTWM2OD1{Mz64NFU6KM7:TR?= M4XtbHNCVkeHUh?=
COR-L88 MoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f1O2lEPTB;MkOuPVQ4PSEQvF2= NGfOcGFUSU6JRWK=
TGBC24TKB NXrLV3dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HDd2lEPTB;MkSuNFMyOiEQvF2= NHK0R5RUSU6JRWK=
HCC1937 M1LEO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nJbWlEPTB;MkSuNUDPxE1? M3rTd3NCVkeHUh?=
RS4-11 NXjGVZZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonzTWM2OD1{ND6xOFIh|ryP NHfje3ZUSU6JRWK=
HCC38 NX[3UXV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\RTWM2OD1{ND6yN|k1KM7:TR?= MlLUV2FPT0WU
RPMI-2650 MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJ2Lk[xOlIh|ryP M37RPXNCVkeHUh?=
P12-ICHIKAWA NU\vSGk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorzTWM2OD1{ND62NlU5KM7:TR?= NX\seWdZW0GQR1XS
YAPC NHHvc5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjreXFKSzVyPUK0MlgzOTRizszN MXTTRW5ITVJ?
NB13 NUfGVHZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LJSWlEPTB;MkWuNlYyOSEQvF2= NIjJNmtUSU6JRWK=
SK-N-AS M1rYRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnVdoNKSzVyPUK1Mlg2QDRizszN M4\qSXNCVkeHUh?=
SK-N-DZ M4jWOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn35TWM2OD1{Nj6wOFkh|ryP MnGxV2FPT0WU
LS-411N MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGGwN4tKSzVyPUK2MlIxOzhizszN MmDYV2FPT0WU
NCI-H810 NGXGWXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojQTWM2OD1{Nj6zNVEzKM7:TR?= NHG1V5FUSU6JRWK=
NCI-SNU-1 M3;qZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJ4LkW0OVQh|ryP NGPs[ndUSU6JRWK=
HH NVLJWmd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3OxdWlEPTB;Mk[uOVUzQSEQvF2= MVfTRW5ITVJ?
U-2-OS NXTGS|NjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXCTWM2OD1{Nj63N|gzKM7:TR?= NGDre3VUSU6JRWK=
SF539 NXvYSVdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\sSlBxUUN3ME2yOk45ODF6IN88US=> MVzTRW5ITVJ?
NCI-H2052 MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\HfXlKSzVyPUK3MlA5PiEQvF2= NIT3bYNUSU6JRWK=
A673 NGT0ellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\OcppKSzVyPUK3MlIyODJizszN M4DRNXNCVkeHUh?=
WM-115 M3POPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFX4R3pKSzVyPUK3Mlc4PjdizszN Mnv6V2FPT0WU
SW48 NFKxfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfROm9KSzVyPUK3MlgxODVizszN M1qxW3NCVkeHUh?=
NOMO-1 NVXtS3RxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTOdno2UUN3ME2yO{45PTN{IN88US=> MVvTRW5ITVJ?
PC-3 MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;NUWlEPTB;MkeuPFk1OSEQvF2= M4PxU3NCVkeHUh?=
UMC-11 NFftS4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHXRlYxUUN3ME2yO{46OzR|IN88US=> M3fURnNCVkeHUh?=
U-118-MG MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXjXnFzUUN3ME2yPE4xOTJ|IN88US=> NIXEO2tUSU6JRWK=
NCI-H2452 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnDTWM2OD1{OD6wPFIzKM7:TR?= NIPJXWJUSU6JRWK=
CAMA-1 NEPYVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2j6UGlEPTB;MkiuPFU3PCEQvF2= M2m2UHNCVkeHUh?=
MC-IXC NXfXWWI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXibIt{UUN3ME2yPU4zOzZ4IN88US=> NX;mWXNZW0GQR1XS
ES4 NFvXS4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7oVYJEUUN3ME2yPU4{OTd{IN88US=> MoH3V2FPT0WU
BHT-101 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGKzWnRKSzVyPUK5MlMzOSEQvF2= NXriVZN7W0GQR1XS
KP-4 M33Tfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjkVWNQUUN3ME2yPU42OTZizszN NY[0PYpZW0GQR1XS
CAL-54 NY[wdIF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTJ7LkW0OFUh|ryP NHuxWIFUSU6JRWK=
5637 M1jBc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYj0VFlFUUN3ME2yPU43PDJzIN88US=> NEPtOoNUSU6JRWK=
MOLT-16 MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDp[XVKSzVyPUK5MlczPjlizszN MYXTRW5ITVJ?
Ca-Ski M4HrcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TEcGlEPTB;MkmuPVQ3KM7:TR?= Moj1V2FPT0WU
AsPC-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTNyLkCyNVIh|ryP NGjaWo9USU6JRWK=
MSTO-211H NXfQbZgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7KTWM2OD1|MD6xOUDPxE1? NXH6XJRjW0GQR1XS
L-428 NXr3Vo41T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TFcGlEPTB;M{CuOFA2KM7:TR?= MXvTRW5ITVJ?
SW1463 MnjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPreWJKSzVyPUOwMlU{QDNizszN NFGzfWxUSU6JRWK=
NCI-H1648 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTNyLkW1O|Qh|ryP M1;Le3NCVkeHUh?=
CAKI-1 M13Bbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHJTWM2OD1|MD63O|AzKM7:TR?= NWPiTGNuW0GQR1XS
YKG-1 NYeyT44xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HHTGlEPTB;M{GuNFI3OyEQvF2= NIjpO4lUSU6JRWK=
A2058 Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDWTWM2OD1|MT6xNVY1KM7:TR?= NHr5R|NUSU6JRWK=
A375 NXzke|FYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzwTWM2OD1|MT6xOlk3KM7:TR?= MYjTRW5ITVJ?
SNB75 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rESmlEPTB;M{GuNlQ{PSEQvF2= M2eyTXNCVkeHUh?=
SK-HEP-1 NFzVR3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTNzLkSyO|Eh|ryP MXHTRW5ITVJ?
ME-180 MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoL6TWM2OD1|MT62OVQzKM7:TR?= NYjDOY1lW0GQR1XS
NCI-H209 NHXm[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTNzLkiyOFch|ryP NYDoZpJmW0GQR1XS
HC-1 MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTN{LkG0OFYh|ryP NXHMOHVRW0GQR1XS
LB373-MEL-D M{fY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLKTWM2OD1|Mj6xPVcyKM7:TR?= NUTGNJNWW0GQR1XS
SNU-387 M{\DTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYO4fXg1UUN3ME2zNk4{OTlzIN88US=> NWX2OHk1W0GQR1XS
C32 NXuxfWVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTN{LkOzOVMh|ryP MlXaV2FPT0WU
EW-13 NUTrXI9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLxTWM2OD1|Mj65OFA5KM7:TR?= NYXmUldnW0GQR1XS
BFTC-905 NVS1eGR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\pTmlEPTB;M{OuOVE{PiEQvF2= M1HYcXNCVkeHUh?=
NCI-H1299 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmC3TWM2OD1|Mz61OlIyKM7:TR?= MYrTRW5ITVJ?
LU-135 M2TLR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PlV2lEPTB;M{OuPFAyKM7:TR?= MWjTRW5ITVJ?
NCI-H2122 M2e3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrxTWM2OD1|Mz65PVY3KM7:TR?= MX3TRW5ITVJ?
SK-LMS-1 M2PqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTN2LkSxNFch|ryP MlS4V2FPT0WU
LNCaP-Clone-FGC MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoT5TWM2OD1|ND64OVE2KM7:TR?= NHrGb2tUSU6JRWK=
NCI-H1092 NYTuUnUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTnTWM2OD1|NT6yO|Q4KM7:TR?= MWTTRW5ITVJ?
MS-1 NF61dnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDUeJJ6UUN3ME2zOU4{ODN6IN88US=> Mn;5V2FPT0WU
KYSE-510 NIL5PHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfBTWM2OD1|NT61NFQzKM7:TR?= NIfWV3lUSU6JRWK=
NCI-H1793 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPKR4JHUUN3ME2zOU43PTR3IN88US=> MULTRW5ITVJ?
MIA-PaCa-2 NYnmdlczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fu[2lEPTB;M{[uNFQ6PiEQvF2= NUDrXYJYW0GQR1XS
EW-22 NF7jOWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzqVFV3UUN3ME2zOk41ODd{IN88US=> MWDTRW5ITVJ?
IGR-1 NFPScJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[5PWxKSzVyPUO2MlgyQDRizszN NXW1NXhWW0GQR1XS
HT-1080 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnq1TWM2OD1|Nz6xNlUh|ryP M1LrR3NCVkeHUh?=
M14 M2nmRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUi3bWs4UUN3ME2zO{4yPjR{IN88US=> MVPTRW5ITVJ?
786-0 Mlu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;rTItKSzVyPUO3MlI4QTRizszN NYLIZlYxW0GQR1XS
MZ2-MEL NV;UPVJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHu0OJBKSzVyPUO3MlQ2ODFizszN M1zpT3NCVkeHUh?=
NCI-H510A MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTN5Lkm0NVIh|ryP NVLvflA5W0GQR1XS
LAN-6 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTRTWM2OD1|Nz65OVgzKM7:TR?= M3L2NnNCVkeHUh?=
SW620 NF\2OGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{CwW2lEPTB;M{iuOFk4PCEQvF2= MXnTRW5ITVJ?
LB2241-RCC M1TGS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm0TXBKSzVyPUO5MlgzODVizszN MkmyV2FPT0WU
Detroit562 NV7zNY1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PvZ2lEPTB;NECuNVI3QCEQvF2= MoO0V2FPT0WU
HN Mm\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLaTWM2OD12MD6xO|gzKM7:TR?= MYrTRW5ITVJ?
HCT-15 M2O5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{iyXWlEPTB;NECuOVkxPyEQvF2= M3;BPHNCVkeHUh?=
C2BBe1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:xVWx5UUN3ME20NE46OTV5IN88US=> M{fZN3NCVkeHUh?=
A498 NVHJSolCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTjWHMzUUN3ME20NU4{ODF3IN88US=> M3LGNnNCVkeHUh?=
SK-MEL-24 NV\RdFY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYS1R4NrUUN3ME20NU41PzJ3IN88US=> NF\Fd4pUSU6JRWK=
OVCAR-5 M{e5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTRzLke3Olch|ryP NV3yc2lWW0GQR1XS
NCI-H1792 NX3JXVhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTRzLkm4NlEh|ryP NYTp[VdoW0GQR1XS
KOSC-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\ZUWlEPTB;NEKuNlY6QSEQvF2= MX3TRW5ITVJ?
Mo-T NIq1dWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nFc2lEPTB;NEKuPFk2QCEQvF2= NWT2cXMyW0GQR1XS
CFPAC-1 M{Hoemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLqSXlmUUN3ME20N{41QTR2IN88US=> NG\LS|lUSU6JRWK=
CAL-51 M3f2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjjU2d4UUN3ME20N{42PjB3IN88US=> NFn1fZRUSU6JRWK=
RH-18 NVX5[21uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\U[mlEPTB;NEOuPFA2KM7:TR?= NEXHcYhUSU6JRWK=
EC-GI-10 MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jrXGlEPTB;NEOuPFM1PyEQvF2= M2HodHNCVkeHUh?=
HSC-2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLCTWM2OD12ND6wNFkh|ryP MkLSV2FPT0WU
ML-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTR3LkK2NlEh|ryP NYLkfIdNW0GQR1XS
KNS-81-FD MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnLVFNQUUN3ME20OU44OzZ3IN88US=> MYLTRW5ITVJ?
NB6 NGH0cGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTR4LkGxNUDPxE1? NH\1TotUSU6JRWK=
MCF7 NIPrPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fROGlEPTB;NE[uOVU{OyEQvF2= M4TRZ3NCVkeHUh?=
P30-OHK NWruPVNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLuNYxKSzVyPUS2MlgyOTdizszN MkC3V2FPT0WU
BPH-1 NX;yXZdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj5UVRqUUN3ME20Ok46QDB3IN88US=> MmnVV2FPT0WU
U251 NFfxb2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DqOWlEPTB;NE[uPVk1KM7:TR?= MUHTRW5ITVJ?
MKN1 M3H0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL6PHFKSzVyPUS3MlUyOzdizszN Mn3JV2FPT0WU
A431 MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[4bWlEPTB;NEeuPFM{QCEQvF2= M3KybHNCVkeHUh?=
C8166 MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD1TWM2OD12OT6yNFM6KM7:TR?= MXzTRW5ITVJ?
HEL M3LHdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfZTWM2OD12OT60NFY1KM7:TR?= MojOV2FPT0WU
RMG-I NX;C[FZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PKTWlEPTB;NEmuOFQ1PCEQvF2= M{DW[nNCVkeHUh?=
CAL-72 NUj0UFRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTR7Lk[wO|Uh|ryP NH3mTGZUSU6JRWK=
SW962 NGnCcWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTR7LkmzN|Ih|ryP MXzTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.

Protocol

Kinase Assay:

[1]

+ Expand

Cellular receptor kinase phosphorylation assay:

Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.
Cell Research:

[2]

+ Expand
  • Cell lines: HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
  • Concentrations: 1 nM - 10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
  • Formulation: 0.5% carboxymethylcellulose (CMC)
  • Dosages: 10, 30 or 100 mg/kg
  • Administration: Oral daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 35 mg/mL warmed (90.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
0.5% CMC
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage powder
Synonyms AG 013736

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02156895 Not yet recruiting Advanced Renal Cell Carcinoma Pfizer June 2017 --
NCT02782403 Not yet recruiting Leukemia M.D. Anderson Cancer Center|Pfizer September 2016 Phase 1|Phase 2
NCT02859012 Recruiting Recurrent ACC, metastaticACC, Unreaectable ACC Seoul National University Hospital September 2016 Phase 2
NCT02853331 Recruiting Renal Cell Carcinoma Merck Sharp & Dohme Corp. September 2016 Phase 3
NCT02762513 Recruiting Squamous Cell Carcinoma of the Head and Neck University of Michigan Cancer Center|National Comprehensive Cancer Network August 2016 Phase 2
NCT02684006 Recruiting Renal Cell Cancer Pfizer March 2016 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We would like to store at -80℃ after it dissolved in CMC. Do you have any infomation about the suggested concentration in CMC?

  • Answer:

    Axitinib in 0.5% CMC at up to 30mg/ml is a suspension for oral gavage administration only. We don't suggest customer to freeze down the solution but to make fresh if possible. Customer can store it for 1-2 weeks at 4 degree for continuous use.

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Axitinib | Axitinib supplier | purchase Axitinib | Axitinib cost | Axitinib manufacturer | order Axitinib | Axitinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID